Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 433-444

  Collins Jr , R H ^a   Shpilberg, O ^a   Drobyski, W R ^a   Porter, D L ^a   Giralt, S ^a   Champlin, R ^a   Goodman, S A ^a   Wolff, S N ^a   Hu, W ^a   Verfaillie, C ^a   List, A ^a   Dalton, W ^a   Ognoskie, N ^a   Chetrit, A ^a   Antin, J H ^a   Nemunaitis, J ^a  

^a Texas Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CHILD; CHRONIC MYELOID LEUKEMIA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKAPHERESIS; LEUKOCYTE TRANSFUSION; MAJOR CLINICAL STUDY; MALE; PANCYTOPENIA; PRIORITY JOURNAL;

EID: 2942712161     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.433     Document Type: Article

References (44)

1. Barnes D, Louti J, Neal F: Treatment of murine leukemia with x-rays and homologous bone marrow. Br Med J 2:626-630, 1956
2. Truitt R, Johnson B: Principles of graft-vs.-leukemia reactivity. Biol Bone Marrow Transplant 1:61-68, 1995
3. Weiden PL, Sullivan KM, Flournoy N, et al.: The Seattle Marrow Transplant Team: Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529-1533, 1981
4. Gale RP, Champlin RE: How does bone-marrow transplantation cure leukaemia? Lancet 2:28-30, 1984
5. Horowitz MM, Gale RP, Sondel PM, et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562, 1990
6. Odom LF, August CS, Githen JH, et al.: Remission of relapsed leukaemia during graft-versus-host reaction. Lancet 2:537-540, 1978
7. Higano CS, Brixey M, Bryant EM, et al.: Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 50:175-177, 1990
8. Collins RH Jr, Rogers ZR, Bennett M, et al.: Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 10:391-395, 1990
9. Kolb HJ, Mittermuller J, Clemm C, et al.: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-2465, 1990
10. Bar BMAM, Schattenberg A, Mesnick EJBM, et al.: Donor leukocyte infusions for chronic myeloid leukemia after allogeneic bone marrow transplantation. J Clin Oncol 11:513-519, 1993
11. Drobyski WR, Keever CA, Roth MS, et al.: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82:2310-2318, 1993
12. Hertenstein B, Wiesneth M, Novotny J, et al.: Interferon-α and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 56:1114-1118, 1993
13. Szer J, Grigg AP, Phillips GL, et al.: Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplant 11:109-111, 1993
14. Helg C, Roux E, Beris P, et al.: Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 12:125-129, 1993
15. Porter DL, Roth MS, McGarigle C, et al.: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100-106, 1994
16. Van Rhee F, Lin F, Cullis JO, et al.: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377-3383, 1994
17. Collins RH, Piñeiro L, Nemunaitis J, et al.: Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation. Transfusion 35:891-898, 1995
18. Kolb HJ, Schattenberg A, Goldman JM, et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-2050, 1995
19. Tricot G, Vesole DH, Jagannath S, et al.: Graft-versus-myeloma effect: proof of principle. Blood 87:1196-1198, 1996
20. Mackinnon S, Papadopoulos EB, Carabasi MH, et al.: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of GVL responses from GVHD. Blood 86:1261-1268, 1995
21. Giralt S, Hester J, Huh Y, et al.: CD8-depleted lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337-4343, 1995
22. Slavin S, Naparstek E, Nagler A, et al.: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87:2195-2204, 1996
23. Verdonck LF, Lokhorst HM, Dekker AW, et al.: Graft-versus-myeloma effect in two cases. Lancet 347:800-801, 1996
24. Antin JH: Graft-versus-leukemia: No longer an epiphenomenon. Blood 82:2273-2277, 1993
25. Speck B, Bortin MM, Champlin R, et al.: Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1:665-668, 1984
26. Glucksberg H, Storb R, Fefer A, et al.: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18:295-304, 1974
27. Shulman HM, Sullivan KM, Weiden PL, et al.: Chronic graft-vs-host syndrome in man. A long-term clinicopathological study of 20 Seattle patients. Am J Med 69:204-217, 1980
28. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
29. Balkwill FR: Interferons. Lancet 1:1060-1063, 1989
30. Upadhyaya G, Guba SC, Sih SA, et al.: Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest 88:2131-2136, 1991
31. Herberman RB, Ortaldo JR, Rubinstein M, et al.: Augmentation of natural and antibody-dependent cell-mediated cytotoxicity by pure human leukocyte interferon. J Clin Immunol 1:149-153, 1981
32. Johnson BD, Drobyski WR, Truitt RL: Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemic reaction without graft-versus-host disease. Bone Marrow Transplant 11:329-336, 1993
33. Jiang YZ, Cullis JO, Kanfer EJ, et al.: T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 11:133-138, 1993
34. Bunjes D, Theobald M, Hertenstein B, et al.: Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells. Bone Marrow Transplant 15:713-719, 1995
35. Higano C, Chielens D, Bryant E, et al.: Alfa-2A-interferon produces durable complete cytogenetic responses in patients with cytogenetic relapse of chronic myelogenous leukemia after marrow transplantation. Blood 86:566a. 1995 (suppl. abstr)
36. Naparstek E, Or R, Nagler A, et al.: T-cell-depleted allogeneic bone marrow transplantation for acute leukemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 89:506-515, 1995
37. Slavin S, Ackerstein A, Weiss L, et al.: Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 10:221-227, 1992
38. Sosman JA, Oettel KR, Smith SD, et al.: Specific recognition of human leukemic cells by allogeneic T-cells: II. Evidence of HLA-D restricted determinants on leukemic cells that are cross-reactive with determinants present on unrelated non-leukemic cells. Blood 75:2005-2016, 1990
39. Faber LM, van Luxemburg-Heijs SA, Wollemze R, et al.: Generation of leukemia-reactive cytotoxic T-lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 176:1283-1289, 1992
40. van Lochem E, de Gast B, Goulmy E: In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 10:181-183, 1992
41. Datta AR, Barrett AJ, Jiang YZ: Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: A model for separating GVHD from GVL reactions. Bone Marrow Transplant 14:517-524, 1994
42. Plautz G, Nabel EG, Nabel GJ: Selective elimination of recombinant genes in vivo with a suicide retroviral vector. New Biol 3:709-715, 1991
43. Tiberghien P, Reynolds CW, Keller J, et al.: Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T-lymphocytes: An approach for specific in vivo donor T cell depletion after bone marrow transplantation. Blood 84:1333-1341, 1994
44. Bonini C, Verzeletti S, Srvida P, et al.: Transfer of the HSV-TK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity after allo-BMT. Blood 84:110a, 1994 (suppl 1, abstr)